Sarcopenia Prevalence Using Different Definitions in Older Community-Dwelling Canadians.

OBJECTIVES: Sarcopenia is a debilitating condition affecting millions of individuals worldwide and is defined with different criteria. The objective of this study was to determine the prevalence of sarcopenia in older Canadians using three internationally accepted criteria. DESIGN: Observational cohort study. SETTINGS AND PARTICIPANTS: Data from 12,592 subjects [6,314 males (50.1%), 6,278 females (49.9%)] ≥65 years old in the Canadian Longitudinal Study on Aging were included. MEASUREMENTS: Appendicular lean mass (ALM; kg) and appendicular lean mass index (ALM kg/height in m2) were collected from dual X-ray absorptiometry measurements. Physical performance was assessed using the 4-m gait speed test, and muscle strength was measured by hand dynamometry. Sarcopenia was defined according to criteria put forth by the International Working Group on Sarcopenia (IWGS), Foundation for the National Institutes of Health (FNIH) Sarcopenia Project, and revised European Working Group on Sarcopenia in Older People (EWGSOP). Positive and negative percent agreements and Cohen's kappa (κ) described the agreement among sarcopenia definitions. RESULTS: Among the evaluated criteria, gait speed ≤ 1.0 m/s (IWGS definition of slowness) was the most frequently identified deficit (56.8% males, 57.2% females). The prevalence of sarcopenia ranged from 1.4 to 5.2% in males and 1.6 to 7.2 % in females among the different definitions. Positive percent agreement values among criteria were generally low (range: 1.5 - 55.3%) and corresponded to κ indicating none to minimal agreement (0.01 - 0.23). Negative percent agreement values were ≥ 95%. CONCLUSION: Sarcopenia prevalence was relatively low in older Canadian adults and current definitions had poor agreement in diagnosing individuals as sarcopenic.

Fat mass to fat-free mass ratio reference values from NHANES III using bioelectrical impedance analysis.

BACKGROUND & AIM: Low fat-free mass (FFM) or high fat mass (FM) are abnormal body composition phenotypes associated with morbidity. These conditions in combination lead to worse health outcomes, and can be identified by a high FM/FFM ratio. Here, we developed sex, age, and body mass index (BMI) stratified, population-based FM/FFM reference values using bioelectrical impedance analysis (BIA) measurements. METHODS: White, non-Hispanic individuals aged 18-90 years old with data for weight, stature and BIA resistance measures from the third National Health and Nutrition Examination Survey (NHANES) III were included. Previously validated and sex-specific BIA prediction equations were used to calculate FM and FFM. FM/FFM values were generated at 5th, 50th and 95th percentiles for each sex, age (18-39.9, 40-59.9, 60-69.9 and 70-90 years), and BMI category (underweight, normal weight, overweight, class I/II and class III obesity). RESULTS: A total of 6372 individuals who had estimated FM and FFM values were identified (3366 females, 3006 males). Median values of FM/FFM were 0.24 and 0.40 for young (≤39.9 years) males and females with normal BMI, and 0.34 for males and 0.59 for females who were overweight. For elderly individuals aged >70 years, median FM/FFM for males and females were respectively 0.28 and 0.45 for those with normal BMI, and 0.37 and 0.61 for those in the overweight category. CONCLUSIONS: These FM/FFM reference values provide information on body composition characteristics that account for age, sex and BMI, which can be useful to identify individuals at risk for body composition abnormalities.

Key determinants of energy expenditure in cancer and implications for clinical practice.

Great discrepancies exist in the reported prevalence of altered energy metabolism (hypo- or hypermetabolism) in cancer patients, which is likely due to the vast array of phenomena that can affect energy expenditure in these patients. The purpose of this review was to critically evaluate key determinants of energy expenditure in cancer and the relevance for clinical practice. Resting energy expenditure (REE) is the largest and most commonly measured component of total energy expenditure. In addition to the energetic demand of the tumor itself, REE may be increased due to changes in inflammation, body composition and brown adipose tissue activation. Energy expenditure from physical activity is often lower in cancer compared with healthy populations, and there is evidence to suggest that the thermic effect of food might also be blunted and affected by cancer therapy. Although accurate assessment of energy metabolism is a cornerstone of adequate nutritional therapy, prediction methods often do not capture the true energy expenditure of most cancer patients. In fact, limits of agreement of prediction equations may range from 40% below to 30% above measured REE. Such variability highlights the need for a more comprehensive understanding of energy expenditure in cancer and the value of accurately assessing the energy needs of these patients.